Friday, 16 October 2026European Markets

EU Regulations & Policy

2 articles

EU AI Act watermarking mandate drives security research surge as vulnerabilities emerge

EU AI Act watermarking mandate drives security research surge as vulnerabilities emerge

The EU AI Act's watermarking requirements for AI-generated content are fueling increased research into attack methods, following NTT DATA's December 2025 disclosure of vulnerabilities. Security experts predict an arms race between watermarking implementation and circumvention techniques as the regulation takes effect.

ViaNews Editorial Team (Europe)•
The Monolith Problem: Why Europe's AI Governance Must Break With Big Tech's One-Size-Fits-All Model

The Monolith Problem: Why Europe's AI Governance Must Break With Big Tech's One-Size-Fits-All Model

Leading AI researchers are building a compelling case that centralised, large-scale AI development is structurally unsafe and economically exclusionary — and their arguments carry direct implications for European regulators still defining what the AI Act means in practice. At stake is whether the EU will entrench the dominance of a handful of American and Chinese technology giants, or chart a genuinely alternative path.

ViaNews Editorial Team (Europe)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com